Juan Mundisugih

Dr. Juan Mundisugih

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2023 in Heart, Lung and Circulation
Verified
Journal Article
Closed access
JMJuan Mundisugih
Juan Mundisugih
KFKyle B. Franke
Kyle B. Franke
Phillip J TullyPhillip J Tully
Phillip J Tully
DMDian A. Munawar
Dian A. Munawar
SKSaurabh Kumar
Saurabh Kumar
RMRajiv Mahajan
Rajiv Mahajan

18 June 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
JMJuan Mundisugih
Juan Mundisugih
DRDhanya Ravindran
Dhanya Ravindran
EKEddy Kizana
Eddy Kizana
Right dominant arrhythmogenic cardiomyopathy, commonly known as Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC), represents a formidable challenge in cardiovascular medicine, as conventional therapies are commonly ineffective in impeding disease progression and the development of end-stage heart failure. Recombinant adeno-associated virus (AAV)-mediated gene therapy presents a promising avenue for targeted therapeutic interventions, potentially revolutionising treatment approaches for ARVC patients. Encouraging results from preclinical studies have sparked optimism about the possibility of curing specific subtypes of ARVC in the near future. This narrative review delves into the dynamic landscape of genetic therapy for ARVC, elucidating its underlying mechanisms and developmental stages, and providing updates on forthcoming trials. Additionally, it examines the hurdles and complexities impeding the successful translation of ARVC genetic therapies into clinical practice. Despite notable scientific advancements, the journey towards implementing genetic therapies for ARVC patients in real-world clinical settings is still in its early phases.

7 February 2024 in Heart Rhythm
Verified
Journal Article
Open access
JMJuan Mundisugih
Juan Mundisugih
SKSaurabh Kumar
Saurabh Kumar
EKEddy Kizana
Eddy Kizana
Cardiac tachyarrhythmia presents a significant health care challenge, causing notable morbidity and mortality. Conventional treatments have limitations and potential risks, resulting in an elevated disease burden. Adeno-associated virus (AAV)-mediated gene therapy holds promise as a potential future treatment option. Therefore, we aimed to provide a measured overview of the latest developments in this rapidly growing field. PubMed and Embase databases were searched up to January 2024. Studies that employed AAV as a vector for delivery of therapeutic agents to treat cardiac tachyarrhythmia were included. Of the 26 studies included, 20 published in the last 5 years. There were 22 novel molecular targets identified. More than 80% of the included studies employed small-animal models or used AAV9. In atrial fibrillation preclinical studies, AAV-mediated gene therapy reduced atrial fibrillation inducibility by 81% (odds ratio, 0.19 [0.08-0.45]; P < .01). Similarly, for acquired and inherited ventricular arrhythmia, animal models receiving gene therapy had less inducible ventricular arrhythmia (odds ratio, 0.06 [0.03-0.11]; P < .01). This review highlights the rapid progress of AAV-mediated gene therapy for cardiac tachyarrhythmia. Although these investigations are currently in the early stages of clinical application, they present promising prospects for gene therapy. (PROSPERO registry: CRD42023479448).

1 June 2018 in Heart, Lung and Circulation
Verified
Journal Article
Closed access
LDLuke P. Dawson
Luke P. Dawson
JWJosephine Warren
Josephine Warren
JMJuan Mundisugih
Juan Mundisugih
VNViveka Nainani
Viveka Nainani
WCWilliam Chan
William Chan
JSJames A. Shaw
James A. Shaw

1 April 2024 in Circulation: Genomic and Precision Medicine
Verified
Journal Article
Closed access
JMJuan Mundisugih
Juan Mundisugih
EKEddy Kizana
Eddy Kizana

2 September 2019 in Progress in Transplantation
Verified
Journal Article
Closed access
PDF file
JMJuan Mundisugih
Juan Mundisugih
HFHimavan Fernando
Himavan Fernando
PBPeter Bergin
Peter Bergin
JHJames Hare
James Hare
DKDavid Kaye
David Kaye
ATAndrew J. Taylor
Andrew J. Taylor
Renal dysfunction is a common complication following heart transplantation that may be worsened by the early initiation of calcineurin inhibitors. Antithymocyte globulin (ATG) or basiliximab has been used to delay or avoid calcineurin inhibitors. The most effective strategy for preventing early acute cellular rejection in this context is uncertain. We retrospectively reviewed all heart transplant cases between January 2012 and June 2017. The standard therapy consisted of mycophenolate mofetil, prednisolone, and tacrolimus. In patients at high risk of post-transplant renal dysfunction, an early calcineurin inhibitor-free regimen with basiliximab and/or ATG was used. Patients were assigned to cohorts based on the initial immunosuppressive strategy. The primary end point was the freedom rate of acute cellular rejection within 4 weeks post-transplant. Of 93 cases, 21 patients received standard therapy, 64 patients received an initial calcineurin inhibitor-free regimen with basiliximab, and 8 patients received ATG and basiliximab. Freedom from acute rejection was greater in the ATG plus basiliximab group (all rejection free), compared to 40 (63%) of 64 patients treated with basiliximab and 10 (48%) of 21 patients treated with standard therapy (P < .05, log rank test). In patients treated with basiliximab, early administration (<24 hours) was associated with a higher freedom from acute rejection compared to ≥24 hours, (72% vs 29%, P < .05). The combination of ATG and basiliximab was more effective in preventing acute cellular rejection. In those patients treated with basiliximab, rejection rates were no worse than standard therapy; however, it was only effective when administered within 24 hours.